<kbd dir="TpCbfGse"></kbd> Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2011 Aug;3(8):495-503.
doi: 10.1002/emmm.201100154. Epub 2011 Jul 11.

A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer

Fabrizio Bianchi  1 , Francesco Nicassio, Matteo Marzi, Elena Belloni, Valentina Dall'olio, Loris Bernard, Giuseppe Pelosi, Patrick Maisonneuve, Giulia Veronesi, Pier Paolo Di Fiore
Affiliations

A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer

Fabrizio Bianchi (VSports手机版) et al. EMBO Mol Med. 2011 Aug.

Abstract

Lung cancer is the first cause of cancer mortality worldwide, and its early detection is currently the main available strategy to improve disease prognosis VSports手机版. While early diagnosis can be successfully achieved through tomography-based population screenings in high-risk individuals, simple methodologies are needed for effective cancer prevention programs. We developed a test, based on the detection of 34 microRNAs (miRNAs) from serum, that could identify patients with early stage non-small cell lung carcinomas (NSCLCs) in a population of asymptomatic high-risk individuals with 80% accuracy. The signature could assign disease probability accurately either in asymptomatic or symptomatic patients, is able to distinguish between benign and malignant lesions, and to capture the onset of the malignant disease in individual patients over time. Thus, our test displays a number of features of clinical relevance that project its utility in programs for the early detection of NSCLC. .

PubMed Disclaimer

Figures

Figure 1
Figure 1. Study design

  1. Sera were obtained from two independent collections: (i) from the COSMOS study [59 non-small cell lung carcinomas (NSCLCs), 69 normal, 33 nodules, 13 sera before disease onset (BDO)], and (ii) from an unrelated serum collection of symptomatic cases [36 NSCLCs (from symptomatic patients), 15 PHs]. COSMOS NSCLC and normal sera were divided into a training set and a testing set (N, normal; T, tumour) VSports最新版本. Additional sets were used for other clinical validations, as shown in the figure and explained in the main text.

  2. A total of 365 miRNA assays (Table SII of Supporting Information) were employed in the screening. A series of tests was implemented to exclude those miRNAs that did not meet a number of stringent criteria for inclusion in the final analysis (see Fig S1 and Table SII of Supporting Information for details). This led to the selection of 147 miRNAs that were used for all analyses presented in the study V体育平台登录.

Figure 2
Figure 2. The 34-miRNA diagnostic model

  1. Receiver operating characteristic (ROC) curves of the 34-miRNA diagnostic model (curves are presented in two separate panels solely for reasons of clarity) V体育官网入口. Colour codes are as per the ‘legend’. TR, training set; TS, testing set; TS-AC, testing set considering only ACs; TS-SCC, testing set considering only SCCs; TS-Stage I, testing set considering only stage I tumours; TS-Stage II–IV, testing set considering all other tumour stages.

  2. Forest plot showing the 34-miRNA model prediction strength in the testing set (all, 30 normal and 34 tumours) stratified by available clinical-pathological parameters VSports在线直播. Triangles represent the odds ratios; lines represent the relative 95% confidence intervals (nominal logistic regression). Age (years) and packs/year (p/y) cut-offs were defined by the relative averages in the 64 patients. p-Value were <0. 01 in all analyses (two-tails Fisher's exact test).

  3. Risk of cancer based on the 34-miRNA risk model in NSCLC patients (separately for ACs and SCCs) from the testing set (left panel) and symptomatic cases (right panel). Average risk scores and p-value (ANOVA) are also shown V体育2025版.

Figure 3
Figure 3. Performance of the 34-miRNA diagnostic model under various conditions of clinical interest

  1. Risk index in patients with LD-CT detected benign nodules (NOD), or normal individuals (N). Average risk scores and p-value (Welch's t-test) are also shown.

  2. Risk index in patients before disease onset (BDO) and after the onset of disease (AC, SCC). Average risk scores and p-value (one-tailed paired t-test) are also shown.

  3. Risk index in patients with breast cancer (BC) or benign breast nodules (NOD). Average risk scores and p-value (Welch's t-test) are also shown.

See this image and copyright information in PMC

References

    1. Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258:243–253. - PMC - PubMed
    1. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007;297:953–961. - PubMed
    1. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108:3713–3718. - PMC - PubMed
    1. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006. - PubMed
    1. Chien CR, Chen TH. Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. Int J Cancer. 2008;122:2594–2599. - PubMed (V体育ios版)

"V体育ios版" Publication types